Brain Research 1987-12-29

Chlorpromazine, but not chlorpromazine sulphoxide, stimulates transmitter release from motor nerve terminals.

Z Y Sahaf, S J Publicover, Z.Y. Sahaf, S.J. Publicover

Index: Brain Res. 437(2) , 397-401, (1987)

Full Text: HTML

Abstract

Treatment of frog neuromuscular preparations with chlorpromazine (5 mumol/l) resulted in a marked rise in miniature endplate potential (MEPP) frequency of greater than 100% within 30 min, and an increase in evoked transmitter release (quantal content 5-15) of about 35%. Treatment with chlorpromazine sulphoxide (5 microM), a derivative of chlorpromazine with a much lower affinity for calmodulin, had very little effect on either form of transmitter release. It is concluded that stimulatory effects of calmodulin-binding drugs at the nerve terminal may well be exerted through calmodulin inhibition. The stimulatory effect of chlorpromazine on MEPP frequency was markedly reduced in preparations bathed in EGTA-containing Ca2+-free saline, but the response was largely restored by raising the temperature by 3-4 degrees C. It is argued that despite this partial dependence on [Ca2+]o, stimulation of transmitter secretion by chlorpromazine is likely to be mediated by inhibition of calmodulin-activated Ca2+-ATPases, and consequent elevation of [Ca2+]i.


Related Compounds

Related Articles:

[Simultaneous determination of chlorpromazine and promethazine and their main metabolites by capillary electrophoresis with electrochemiluminescence].

2012-09-01

[Se Pu 30(9) , 938-42, (2012)]

Free radical production by chlorpromazine sulfoxide, an ESR spin-trapping and flash photolysis study.

1986-07-01

[Photochem. Photobiol. 44(1) , 5-10, (1986)]

Involvement of erythrocyte skeletal proteins in the modulation of membrane fluidity by phenothiazines.

1987-12-15

[Biochemistry 26(25) , 8133-7, (1987)]

Therapeutic monitoring of chlorpromazine. IV: Comparison of a new high-performance liquid chromatographic method with radioimmunoassays for parent drug and some of its major metabolites.

1987-09-01

[Ther. Drug Monit. 9(3) , 358-65, (1987)]

Therapeutic monitoring of chlorpromazine II: Pitfalls in whole blood analysis.

1985-01-01

[Ther. Drug Monit. 7(4) , 472-7, (1985)]

More Articles...